19. Sandström M, Garske-Roman U, Granberg D, et al. Individualized dosimetry of kidney and bone marrow in patients undergoing ^{177}Lu-DOTA-octreotate treatment. *J Nucl Med.* 2013;54:33–41.
20. Kolstad A, Madsbu U, Beasley M, et al. Efficacy and safety results of Betalutin® (177-Lu-DOTA-HH1) in a phase 1/2 study of patients with non-Hodgkin B-cell lymphoma (NHL). Presented at: AACR Annual Meeting; New Orleans, Louisiana; 2016.
21. Svensson J, Hagmarker L, Magnander T, Wangberg B, Bernhardt P. Radiation exposure of the spleen during ^{177}Lu-DOTATATE treatment and its correlation with haematological toxicity and spleen volume. *EJNMMI Phys.* 2016;3:15.
22. Kulkarni HR, Prasad V, Schuchardt C, Baum RP. Is there a correlation between peptide receptor radionuclide therapy-associated hematological toxicity and spleen dose? *Recent Results Cancer Res.* 2013;194:561–566.
23. Fisher DR, Shen S, Meredith RF. MIRD dose estimate report no. 20: radiation absorbed-dose estimates for ^{111}In- and ^{90}Y-ibritumomab tiuxetan. *J Nucl Med.* 2009;50:644–652.
24. Vose JM, Wahl RL, Saleh M, et al. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. *J Clin Oncol.* 2000;18:1316–1323.
25. Forrer F, Oechslin-Oberholzer C, Campana B, et al. Radioimmunotherapy with ^{177}Lu-DOTA-rituximab: final results of a phase I/II study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. *J Nucl Med.* 2013;54:1045–1052.
26. Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma. *J Nucl Med.* 1990;31:1257–1268.
27. Kaminski MS, Zasadny KR, Francis IR, et al. Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. *J Clin Oncol.* 1996;14:1974–1981.
28. Zevalin summary of product characteristics. European Medicines Agency website. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000547/WC500049469.pdf. Accessed April 20, 2017.
29. Wiseman GA, Kornmehl E, Leigh B, et al. Radiation dosimetry results and safety correlations from ^{90}Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. *J Nucl Med.* 2003;44:465–474.
30. Assié K, Dieudonne A, Gardin I, Buvat I, Tilly H, Vera P. Comparison between 2D and 3D dosimetry protocols in ^{90}Y-ibritumomab tiuxetan radioimmunotherapy of patients with non-Hodgkin's lymphoma. *Cancer Biother Radiopharm.* 2008;23:53–64.
31. Ljungberg M, Celler A, Konijnenberg MW, Eckerman KF, Dewaraja YK, Sjögreen-Gleisner K. MIRD pamphlet no. 26: joint EANM/MIRD guidelines for quantitative ^{177}Lu SPECT applied for dosimetry of radiopharmaceutical therapy. *J Nucl Med.* 2016;57:151–162.
32. Bexxar: highlights of prescribing information. GSK Source website. https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Bexxar/pdf/BEXXAR.PDF. Published 2013. Accessed April 20, 2017.

Errata

In the article "The SNMMI and EANM Practice Guideline for Small-Bowel and Colon Transit 1.0*" by Maurer et al. (*J Nucl Med*. 2013;54:2004–2013), Table 1 (column 2) incorrectly states that the administered activity for ^{99m}Tc-labeled nonabsorbable markers (solids) is 18.5–37 MBq/kg (0.5–1.0 mCi/kg) and the administered activity for ^{111}In-labeled liquids (DTPA) is 3.7–37 MBq/kg (0.1–1.0 mCi/kg). The correct activities are *18.5–37 MBq (0.5–1.0 mCi)* and *3.7–37 MBq (0.1–1.0 mCi)*, respectively. In addition, Figure 1 (options A, B, and C) incorrectly states that the range for 300 mL ^{111}In water is 3.7–7.4 MBq. The correct range is *3.7–37 MBq*. We regret the errors.

In the article "Evaluation of Radiopharmaceutical Adverse Reaction Reports to the British Nuclear Medicine Society from 2007 to 2016" by Kennedy-Dixon et al. (*J Nucl Med*. 2017;58:2012–2014), the Discussion section incorrectly says that "Silberstein (*8*) found 15 reports of flushing of the face and trunk within minutes of ^{18}F-FDG administration from 15 nuclear medicine facilities in the United States between 2007 and 2011." In fact, the cited Silberstein article (*J Nucl Med*. 2014;55:1308–1310) stated that only one episode of facial and truncal flushing had been reported during that interval. We regret the error.